Brief: Ryvu Therapeutics Achieves First Milestone Under Agreement With Exelixis
26/01/2023 16:08
Jan 26 (Reuters) - Ryvu Therapeutics RVU.WA :
* ACHIEVES FIRST MILESTONE UNDER LICENCE AGREEMENT WITH
EXELIXIS
* SAID MILESTONE ENTITLES COMPANY TO RECEIVE PAYMENT OF $1
MILLION
Source text for Eikon: ID:nEM8dS9mka
Further company coverage: RVU.WA EXEL.O
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project